<SEC-DOCUMENT>0001157523-15-000297.txt : 20150202
<SEC-HEADER>0001157523-15-000297.hdr.sgml : 20150202
<ACCEPTANCE-DATETIME>20150202064555
ACCESSION NUMBER:		0001157523-15-000297
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20150202
FILED AS OF DATE:		20150202
DATE AS OF CHANGE:		20150202

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ICON PLC
		CENTRAL INDEX KEY:			0001060955
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				981067160

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	333-08704
		FILM NUMBER:		15564838

	BUSINESS ADDRESS:	
		STREET 1:		SOUTH COUNTY BUSINESS PARK
		STREET 2:		LEOPARDSTOWN
		CITY:			DUBLIN 18
		STATE:			L2
		ZIP:			00000
		BUSINESS PHONE:		00 353 1 291 2000

	MAIL ADDRESS:	
		STREET 1:		SOUTH COUNTY BUSINESS PARK
		STREET 2:		LEOPARDSTOWN
		CITY:			DUBLIN 18
		STATE:			L2
		ZIP:			00000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ICON PLC  /ADR/
		DATE OF NAME CHANGE:	20010213
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a51030593.htm
<DESCRIPTION>ICON PLC 6-K
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2015 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-size: 10pt; font-family: Times New Roman">
    <p style="text-align: center">
      <br>
      <font style="font-size: 14pt; font-family: Times New Roman"><b>FORM 6-K</b></font><br><br><br><font style="font-size: 14pt"><b>SECURITIES
      AND EXCHANGE COMMISSION</b></font><br><br><br><font style="font-size: 12pt">Washington,
      D.C. 20549</font><br><br><br><font style="font-size: 12pt; font-family: Times New Roman"><b>Report
      of Foreign Private Issuer</b></font><br><font style="font-size: 12pt; font-family: Times New Roman"><b>Pursuant
      to Rule 13a-16 under</b></font><br><font style="font-size: 12pt; font-family: Times New Roman"><b>the
      Securities Exchange Act of 1934</b></font><br><br><br>For the month ended<font style="font-size: 10pt; font-family: Times New Roman">
      February, 2015</font><br><br><br><font style="font-size: 18pt; font-family: Times New Roman"><b>ICON&#160;plc</b></font><br>(R<font style="font-size: 10pt; font-family: Times New Roman">egistrant's
      name)</font><br><br><br>0-29714<br>(Commission file number)<br><br><br>South
      County Business Park, Leopardstown, Dublin 18, Ireland<br>(Address of
      principal executive offices)<br><br>Brendan Brennan, CFO<br>South County
      Business Park Leopardstown, Dublin 18, Ireland.<br>Brendan.Brennan@iconplc.com<br>00-353-1-291-2000<br>(Name,
      telephone number, email and/or facsmile number and address of Company
      contact person)<br><br>
    </p>
    <p>
      Indicate by check mark whether the registrant files or will file annual
      reports under cover Form 20-F or Form 40-F.<br>
    </p>
    <p style="text-align: center">
      &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Yes___<u><b>X</b></u>___&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No___<b>_</b>___<br><br>
    </p>
    <p>
      Indicate by check mark whether the registrant is submitting the Form 6-K
      in paper as permitted by Regulation S-T Rule 101(b)(1):<br>
    </p>
    <p style="text-align: center; white-space: nowrap">
      &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Yes______&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No___<u><b>X</b></u>___<br><br>
    </p>
    <p>
      Indicate by check mark whether the registrant is submitting the Form 6-K
      in paper as permitted by Regulation S-T Rule 101(b)(7):<br>
    </p>
    <p style="text-align: center; white-space: nowrap">
      &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Yes______&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No___<u><b>X</b></u>___<br><br>
    </p>
    <p>
      Indicate by check mark whether the registrant by furnishing the
      information contained in this Form is also thereby furnishing the
      information to the Commission pursuant to Rule 12g3-2(b) under the
      Securities Exchange Act of 1934.<br>
    </p>
    <p style="text-align: center; white-space: nowrap">
      &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Yes___<b>_</b>___&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No___<u><b>X</b></u>___<br><br>
    </p>
    <p style="white-space: nowrap">
      If &quot;Yes&quot; is marked, indicate below the file number assigned to the
      registrant in connection with Rule 12g3-2(b):82&#160;&#160;&#160;&#160;&#160;&#160;<b>N/A</b><br><br>
    </p>
    <div style="width: 100%; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; margin-bottom: 10pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p style="text-align: center">
      <br>
      <u><font style="font-size: 10pt"><b>EXHIBIT&#160;LIST</b></font></u><br>
    </p>
<div style="text-align:left">
    <table cellspacing="0" style="width: 100%; font-size: 10pt; font-family: Times New Roman; margin-bottom: 10.0px">
      <tr>
        <td valign="top" style="text-align: left; width: 8%; padding-left: 0.0px">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <u>Exhibit</u>
          </p>
        </td>
        <td valign="top" style="text-align: left; width: 92%; padding-left: 0.0px">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <u>Description</u>
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 8%">

        </td>
        <td valign="top" style="text-align: left; width: 92%; padding-left: 0.0px">
          &#160;
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; width: 8%; padding-left: 0.0px; padding-right: 0.0px; white-space: nowrap">
          <p style="margin-top: 0px; margin-bottom: 0px">
            99.1
          </p>
        </td>
        <td valign="top" style="text-align: left; width: 92%; padding-left: 0.0px">
          <p style="margin-top: 0px; margin-bottom: 0px">
            ICON plc Press Release issued February 2, 2015
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p style="text-align: center">

    </p>
    <div style="width: 100%; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; margin-bottom: 10pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p style="text-align: center">
      <br>
      <font style="font-size: 10pt"><b>SIGNATURES</b></font>
    </p>
    <p>
      Pursuant to the requirements of the Securities Exchange Act of 1934, the
      Registrant has duly caused this report to be signed on its behalf by the
      undersigned thereunto duly authorized.
    </p>
    <p>

    </p>
<div style="text-align:left">
    <table cellspacing="0" style="width: 100%; font-size: 10pt; font-family: Times New Roman; margin-bottom: 10.0px">
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 55%">

        </td>
        <td valign="top" style="text-align: left; width: 40%; padding-left: 0.0px">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>ICON plc</b>
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 55%">

        </td>
        <td style="width: 40%">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 55%">

        </td>
        <td style="width: 40%">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 55%">

        </td>
        <td style="width: 40%">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 55%">

        </td>
        <td valign="top" style="text-align: left; width: 40%; padding-left: 0.0px">
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;
          </p>
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; width: 5%; padding-left: 0.0px">
          Date:
        </td>
        <td valign="top" style="text-align: left; width: 55%; padding-left: 0.0px">
          <p style="margin-top: 0px; margin-bottom: 0px">
            February 2, 2015
          </p>
        </td>
        <td valign="top" style="text-align: left; width: 40%; padding-left: 0.0px">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <u>/s/ Brendan Brennan</u>
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 55%">

        </td>
        <td valign="top" style="text-align: left; width: 40%; padding-left: 0.0px">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Brendan Brennan
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 55%">

        </td>
        <td valign="top" style="text-align: left; width: 40%; padding-left: 0.0px">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Chief Financial Officer
          </p>
        </td>
      </tr>
    </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a51030593ex99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2015 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-size: 8pt; font-family: Times New Roman">
    <p style="text-align: right">
      <b>Exhibit 99.1</b>
    </p>
    <p style="text-align: center">
      <font style="font-size: 12pt; font-family: Times New Roman"><b>ICON to
      Acquire MediMedia Pharma Solutions </b></font>
    </p>
    <p style="text-align: center">
      <i><font style="font-size: 12pt; font-family: Times New Roman"><b>Extends
      ICON&#8217;s leadership in commercialisation and market access services and
      brings new scientific communications capabilities</b></font></i>
    </p>
    <p>
      DUBLIN--(BUSINESS WIRE)--February 2, 2015--<b>ICON plc (NASDAQ:ICLR), </b>a
      global provider of outsourced development services to the
      pharmaceutical, biotechnology and medical device industries, today
      announced it has agreed, subject to certain customary closing
      conditions, to acquire MediMedia Pharma Solutions for a cash
      consideration of $120 million. MediMedia Pharma Solutions is division of
      MediMedia USA and is owned by Vestar Capital Partners.
    </p>
    <p>
      The acquisition strengthens ICON&#8217;s expertise in scientific
      communications and market access and, together with ICON&#8217;s existing
      Commercialisation and Outcomes practices, creates the industry&#8217;s leading
      integrated scientific communications and market access solution.
    </p>
    <p>
      Headquartered in Yardley, Pennsylvania, MediMedia Pharma Solutions
      includes <i>MediMedia Managed Markets</i> and <i>Complete Healthcare
      Communications. MediMedia Managed Markets </i>is a leading provider of
      strategic payer-validated market access solutions. <i>Complete
      Healthcare Communications</i> is one of the leading medical and
      scientific communication agencies working with medical affairs,
      commercial and brand development teams within life science companies.
      MediMedia Pharma Solutions has supported hundreds of development
      launches and in-market products, spanning over 40 therapeutic classes.
    </p>
    <p>
      Commenting on the acquisition, Ciaran Murray, ICON CEO, said: <i>&#8220;The
      need to demonstrate and communicate the value of new medicines is an
      important global healthcare trend. Through ICON&#8217;s market leading
      commercialisation and outcomes group we are supporting our customers to
      maximise the value of their new drugs. Our acquisition of MediMedia
      Pharma Solutions deepens the expertise of this group and brings us
      outstanding scientific and medical communications capabilities.&#8220; </i>
    </p>
    <div style="width: 100%; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; margin-bottom: 10pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>
      Tim Search, President of MediMedia Pharma Solutions, commented,<i> &#8220;The
      combination of the commercial, scientific, and market access expertise
      of MediMedia Pharma Solutions and ICON creates an unparalleled offering
      that can inform product investment decisions and establish and
      communicate product value. With the shift to evidence-based medicine and
      value-based pricing, we are excited about the expanded expertise and
      capabilities our relationship with ICON brings to our combined
      customers.&#8221;</i>
    </p>
    <p>
      <b>About ICON plc</b>
    </p>
    <p>
      ICON plc is a global provider of outsourced development services to the
      pharmaceutical, biotechnology and medical device industries. The Company
      specialises in the strategic development, management and analysis of
      programs that support clinical development - from compound selection to
      Phase I-IV clinical studies. ICON currently has 10,600 employees,
      operating from 83 locations in 38 countries.
    </p>
    <p>
      Further information is available at <u><i>www.iconplc.com</i></u>
    </p>
    <p>
      <b>About MediMedia Pharma Solutions</b>
    </p>
    <p>
      MediaMedia Pharma Solutions is a combination of MediMedia Managed
      Markets and Complete HealthCare Communications.
    </p>
    <p>
      MediMedia Managed Markets is a leading provider of strategic
      payer-validated market access solutions for the biopharmaceutical and
      medical device industries. Their comprehensive approach includes
      scientific analysis and assessment, research and insights, strategic
      development, tactical development, and program execution. Complete
      HealthCare Communications is one of the largest medical communication
      agencies and is a pioneer in publication services, providing strategic
      consulting, software solutions, and scientific communications to medical
      affairs teams for life sciences firms globally.
    </p>
    <p>
      Further information is available at <u><i>www.medimediamanagedmarkets.com</i></u>
      and <u><i>www.thechcgroup.com</i></u>
    </p>
    <p>
      <b>About Vestar Capital Partners</b>
    </p>
    <p>
      Vestar Capital Partners is a leading U.S. middle-market private equity
      firm specializing in management buyouts and growth capital investments.
      Vestar invests and collaborates with incumbent management teams and
      private owners in a creative, flexible and entrepreneurial way to build
      long-term enterprise value.
    </p>
    <p>
      Vestar targets equity investments in U.S.-based middle-market companies
      with enterprise values ranging from $200 million to $1 billion. Vestar
      has extensive experience investing across a wide variety of industries
      including Consumer, Healthcare, Digital Media, Information Services,
      Diversified Industries, and Financial Services. Since Vestar&#8217;s founding
      in 1988, Vestar funds have completed more than 70 investments in
      companies with a total value of more than $40 billion.
    </p>
    <p>
      Further information is available at <u><i>www.vestarcapital.com</i></u><i>
      </i>
    </p>
    <div style="width: 100%; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt; margin-bottom: 10pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>
      <i>This press release contains forward-looking statements. These
      statements are based on management's current expectations and
      information currently available, including current economic and industry
      conditions. These statements are not guarantees of future performance or
      actual results, and actual results, developments and business decisions
      may differ from those stated in this press release. The forward-looking
      statements are subject to future events, risks, uncertainties and other
      factors that could cause actual results to differ materially from those
      projected in the statements, including, but not limited to, the ability
      to enter into new contracts, maintain client relationships, manage the
      opening of new offices and offering of new services, the integration of
      new business mergers and acquisitions, as well as economic and global
      market conditions and other risks and uncertainties detailed from time
      to time in SEC reports filed by ICON, all of which are difficult to
      predict and some of which are beyond our control. For these reasons, you
      should not place undue reliance on these forward-looking statements when
      making investment decisions. The word &quot;expected&quot; and variations of such
      words and similar expressions are intended to identify forward-looking
      statements. Forward-looking statements are only as of the date they are
      made and we do not undertake any obligation to update publicly any
      forward-looking statement, either as a result of new information, future
      events or otherwise. More information about the risks and uncertainties
      relating to these forward-looking statements may be found in SEC reports
      filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are
      available on the SEC's website at <u>http://www.sec.gov.</u></i>
    </p>
    <p>
      ICON/ICLR-F
    </p>
    <p>

    </p>
    <p>
      CONTACT:<br>ICON plc<br>Investor Relations<br>1-888-381-7923<br>or<br>Brendan
      Brennan, + 353 &#8211;1-291-2000<br>Chief Financial Officer<br>or<br>Simon
      Holmes, + 353 &#8211;1-291-2000<br>EVP Investor Relations and Corporate
      Development<br><u>http://www.iconplc.com</u>
    </p>
    <p>

    </p>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
